Randomized trial showcases improved respiratory function in acute lung injury, suggesting a new therapeutic approach.
Acute lung injury (ALI) remains life-threatening conditions lacking effective disease-modifying therapies. Dysregulated inflammation, oxidative stress, and apoptosis form a self-amplifying pathogenic loop that drives alveolar-capillary barrier disruption, highlighting the urgent need for multifunctional therapeutic strategies. Here, we report a pH-responsive biomimetic nanoplatform, pDA/Esc@ZIF-8, for precision treatment of ALI. Zeolitic imidazolate framework-8 (ZIF-8) was employed to encapsulate the natural anti-inflammatory and antioxidant agent esculin (Esc), while a polydopamine (pDA) coating conferred enhanced colloidal stability, intrinsic reactive oxygen species scavenging activity, and pH-triggered drug release, enabling efficient pulmonary accumulation and sustained local retention. In vitro and in vivo ALI models demonstrated that pDA/Esc@ZIF-8 markedly alleviated lung inflammation, oxidative injury, and epithelial apoptosis, thereby preserving alveolar-capillary barrier integrity and improving respiratory function. Mechanistically, the therapeutic effects were closely associated with modulation of the PI3K/AKT/GSK3β signaling axis, leading to suppression of pro-inflammatory responses, attenuation of oxidative stress, and inhibition of mitochondria-dependent apoptotic pathways. Collectively, this multifunctional nanotherapeutic system integrates pulmonary priority accumulation, microenvironment-responsive release, and pathway-level regulation to interrupt the inflammation-oxidative stress-apoptosis cascade, offering a promising and translatable strategy for the treatment of ALI and related inflammatory lung diseases.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: